Effects of acarbose (Glucobay®) in persons with type 1 diabetes: A multicentre study

Diabetes Research and Clinical Practice

Volumn 41, Issue 2, 1998, Pages 139-145

  Sels, J P J E ^a   Verdonk, H E R ^b   Wolffenbuttel, B H R ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Acarbose; Adverse events; Glycaemic control; Type 1 diabetes

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; FEMALE; FLATULENCE; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACARBOSE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRISACCHARIDES;

EID: 0032144175     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00070-9     Document Type: Article

References (14)

1. Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes, New Engl. J. Med. 329 (1993) 977-986.
2. Jenkins D.J.A., Leeds A.R, Gassull M.A., Cochet B., Alberti K.G.M.M. Decrease in postprandial insulin and glucagon concentrations by guar and pectines. Ann. Int. Med. 86:1977;20-23.
3. Jenkins D.J.A. Lente carbohydrate: a newer approach to the dietary management of diabetes. Diab. Care. 5:1982;634-641.
4. Toeller M. Efficacy of α-glucosidase inhibitors in NIDDM subjects. Eur. J. Clin. Invest. 24(Suppl. 3):1994;31-35.
5. Dimitriades G.D., Karaiskos K., Raptis S. Effects of prolonged (6 months) α-glucosidase inhibition on bloodglucose control and insulin requirements in patients with insulin dependent diabetes mellitus. Horm. Metab. Res. 18:1986;153-255.
6. F. Schumann, K. Janssen, R. Aubell, H.L. Christi, Acarbose in diabetic outpatient treatment: results of a 3 months study, in: W. Creutzfeldt (Ed.), Acarbose: Effects on Carbohydrate and Fat Metabolism, Exerpta Medica, Amsterdam, 1982, pp. 367-372.
7. Gérard J., Luykckx A.S., Lefebvre P.J. Two months treatment with acarbose in type 1 diabetic patients. Diabetologia. 21:1981;446-451.
8. A.E. Lambert, P. Damoiseaux, M. Buysschaert, I. Hillebrand, J.M. Keteslagers, Improved glycaemic control by acarbose in type I diabetes, in: W. Creutzfeldt (Ed.), Acarbose: Effects on Carbohydrate and Fat Metabolism, Exerpta Medica, Amsterdam, 1982, pp. 417-421.
9. G.K.H. Nell, K.F. Weineger, The effects of acarbose (Bay g 4521) on the metabolic state of insulin-dependent diabetic outpatients, in: W.Creutzfeldt (Ed.), Acarbose: Effects on Carbohydrate and Fat Metabolism, Exerpta Medica, Amsterdam, 1982, pp. 486-489.
10. Hollander P., Pi-Sunyer X., Coniff R.F. Acarbose in the treatment of type 1 diabetes. Diab. Care. 20:1997;248-253.
11. Balfour J.A., McTacish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 46:1993;1025-1054.
12. Marena S., Tagliaferro V., Cavallero G. et al. Double-blind cross-over study in type 1 diabetic patients. Diab. Med. 8:1991;674-678.
13. Sels J.P.J.E., Postmes T.J.L., Niemann F., Ebert R., Wolffenbuttel B.H.R., Nieuwenhuijzen Kruseman A.C. Effects of guar bread on type 1 and type 2 diabetes mellitus. Eur. J. Int. Med. 4:1993;193-200.
14. Spengler M., Cagatay M. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Clin. Invest. Med. 18:1995;325-331.